The A beta peptide (synonyms are Beta Amyloid peptide or Abeta peptide) is the main component of amyloid peptide plaques in the brain of patients with Alzheimer's disease. JPT provides a broad selection of chemically synthesized amyloid beta peptides for Alzheimer's disease research. We supply A beta peptides of different lengths and point-mutated versions of A beta (1-42) which are known to be related to the familial forms of Alzheimer's disease. They are provided as HFIP-films (HFIP = hexafluoroisopropanol) which removes any unwanted secondary peptide structure and pre-existing oligomeric/polymeric forms.
Available Amyloid beta A4 peptides
- In vitro staining
- Protein-protein interaction studies
- Western Blot
- Binding experiments
"Synthetic Amyloid Beta Peptides Aid Alzheimer Investigation"
by A. Vandersteen et al.
- All amyloid-ß peptides are well characterized and provided as HFIP-films. This guarantees that all samples contain the same chemically and structurally homogenous material without any unwanted secondary structures
- Production is performed in our German facilities and is ISO 9001:2015 & GCLP certified
- Greatest variety of Abeta sequence modifications in stock - available within days!
- Not found what you are looking for? Request a quote for custom peptide synthesis to obtain your tailored A beta peptide
"Our group focuses on the in vitro study of risk factors in Alzheimer’s disease and, as we experienced that the in-house expression and production of the amyloid beta peptide is notoriously difficult, we are continuously dependent on a high quality supply of a large variety of these peptides from commercial source. We started our collaboration with JPT with their request to test a range of their peptides for the ability to produce toxic oligomers and fibrillar networks and were impressed by the rapid supply of a very wide range of high purity peptides with excellent fibril forming properties and toxicity profiles. JPT has shown real valuable know-how and experience in the field of peptide synthesis by their ability to generate high quality preparations of amyloid beta peptide variants which are known for their difficulty to handle.”
Kerensa Broersen, Assistant Prof., Nanobiophysics Group, University of Twente, Enschede, The Netherlands
Launch Protein Interaction Screen on Peptide Matrix (PRISMA)
Address Sequence Diversity with NEW ULTRA Peptide Microarrays
- JPT's A Beta Peptides Pass the Test!
Read the latest Application Note: Synthetic Amyloid Beta Peptides Aid Alzheimer Investigation by Kerensa Broersen, University of Twente, Enschede